Thursday, January 14 2010 5:26 PM EST2010-01-14 22:26:31 GMT
Although the swine flu vaccine is widely available, the state health department says the highest number of confirmed cases are among young adults. However, it appears that those between 18 and 24 are the least likely to be vaccinated.More >>
Monday, December 14 2009 6:48 PM EST2009-12-14 23:48:57 GMT
Doctors offices and emergency rooms are reporting fewer swine flu cases. But health officials say now is not the time to underestimate the illness.More >>
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Orexigen Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Cowen & Co. Annual Health Care Conference in Boston. The presentation is scheduled for Monday, March 4, 2013 at 3:30 p.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
VP, Corporate Communications and Business Development